Research Sample bioBank
Can’t find what you’re looking for? Contact us.
Or, need help ordering? 805.528.4341
Get Weekly Research Sample Updates in your Inbox:
Hepatitis E Clinical Research Samples
Discovery Life Sciences provides the highest quality Hepatitis E Clinical Research Samples and Residual Diagnostic Specimens from the Life Science Industry’s only convenient online, open access Biobank.
- All Hepatitis E Sample Orders are Packaged for Delivery within 24 Hours.
- All Specimens Ethically Obtained, De-Identified and provided with Highly Annotated Demographic and Clinical Data.
- Select from an HHS/OHRP Compliant Biorepository following ISBER/BBRB Guidelines.
- Packaged in Compliance with all UN Regulations (6.2) and U.S. DOT Hazmat regulations.
Advanced Data View:
Showing 69 of 69 total samples
Buy | Product ID | Sample | Origin | Matrix | Vial (ml) | Quantity | Price | Age | Gender | Ethnicity | Storage Temp | Sample Date | Test 1 | Test Data 1 | Sample Detail 1 | Test 2 | Test Data 2 | Test 3 | Test Data 3 | Sample Detail 3 | Product Details | Price | Buy | Additional Information 1 | Additional Data 1 | Additional Information 2 | Additional Data 2 | Additional Detail 2 | Additional Information 3 | Additional Data 3 | Additional Information 4 | Additional Data 4 | Additional Detail 4 | Additional Information 5 | Additional Data 5 | Additional Information 6 | Additional Data 6 | Additional Detail 6 | Additional Information 7 | Additional Data 7 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DLS13-11678 | Hepatitis E | France | CPD | 2.00 | 12.00 | $250.00 | U/A | U/A | < -70C | 30-Oct-12 | Bio-Evolution PCR Tps Reel | Positive | Bio-Evolution ORF2 PCR | Genotype 3 | Real-Time PCR | 2,940 cps/mL | Sequencing of the ORF2 region | $250.00 | HCV, HIV, HTLV, HBc et AgHBs Neg DGV Neg Syphilis Nég. | |||||||||||||||||||||
| DLS13-11679 | Hepatitis E | France | CPD | 2.00 | 11.00 | $250.00 | U/A | U/A | < -70C | 26-Sep-12 | Bio-Evolution PCR Tps Reel | Positive | Bio-Evolution ORF2 PCR | Genotype 3f | Real-Time PCR | 165,000 cps/mL | Sequencing of the ORF2 region | $250.00 | HCV, HIV, HTLV, HBc et AgHBs Neg DGV Neg Syphilis Nég. Infection Réplicative à HEV | |||||||||||||||||||||
| DLS13-11680 | Hepatitis E | France | CPD | 2.00 | 15.00 | $250.00 | U/A | U/A | < -70C | 17-Sep-12 | Bio-Evolution PCR Tps Reel | Positive | Bio-Evolution ORF2 PCR | Genotype 3f | Real-Time PCR | 2,440 cps/mL | Sequencing of the ORF2 region | $250.00 | Sero HEV-IgG | Neg | Sero HEV-IgM | Neg | HCV, HIV, HTLV, HBc et AgHBs Neg DGV Neg Syphilis Nég. Infection Réplicative à HEV | |||||||||||||||||
| DLS13-11681 | Hepatitis E | France | CPD | 2.00 | 13.00 | $250.00 | U/A | U/A | < -70C | 05-Oct-12 | Bio-Evolution PCR Tps Reel | Positive | Real-Time PCR | 132,000 cps/mL | Sequencing of the ORF2 region | $250.00 | HCV, HIV, HTLV, HBc et AgHBs Neg DGV Neg Syphilis Nég. | |||||||||||||||||||||||
| DLS13-11682 | Hepatitis E | France | CPD | 2.00 | 2.00 | $250.00 | < -70C | Bio-Evolution PCR Tps Reel | Positive | Bio-Evolution ORF2 PCR | Genotype 3c | Real-Time PCR | 502,000 cps/mL | Sequencing of the ORF2 region | $250.00 | HCV, HIV, HTLV, HBc et AgHBs Neg DGV Neg Syphilis Nég. | ||||||||||||||||||||||||
| DLS13-11683 | Hepatitis E | France | CPD | 2.00 | 16.00 | $250.00 | U/A | U/A | < -70C | 15-Oct-12 | Bio-Evolution PCR Tps Reel | Positive | Real-Time PCR | 1,710 cps/mL | $250.00 | HCV, HIV, HTLV, HBc et AgHBs Neg DGV Neg Syphilis Nég. | ||||||||||||||||||||||||
| DLS13-11685 | Hepatitis E | France | CPD | 2.00 | 17.00 | $250.00 | U/A | U/A | < -70C | 12-Nov-12 | Bio-Evolution PCR Tps Reel | Positive | Real-Time PCR | 10,900 cps/mL | Sequencing of the ORF2 region | $250.00 | HCV, HIV, HTLV, HBc et AgHBs Neg DGV Neg Syphilis Nég. | |||||||||||||||||||||||
| DLS17-036561 | Hepatitis E | France | CPD | 1.00 | 3.00 | $250.00 | 63 Y | M | U/A | <-70C | 22-Dec-15 | Altona HEV RT-PCR Kit | 534 copies/mL | WANTAI HEV-IgM Elisa | Positive | WANTAI HEV-IgG Elisa | 0.77 IU/mL | Positive | $250.00 | Genotype | 3f | Additional Results | HCV, HIV, HTLV, HBc, HBsAg Negative. Viral Genome Screening Negative. | |||||||||||||||||
| DLS17-036562 | Hepatitis E | France | CPD | 1.00 | 21.00 | $250.00 | 64 Y | M | U/A | <-70C | 04-Dec-16 | Altona HEV RT-PCR Kit | 23,100 copies/mL | WANTAI HEV-IgM Elisa | Positive | WANTAI HEV-IgG Elisa | 38.5 IU/mL | Positive | $250.00 | Genotype | 3c | Additional Results | HCV, HIV, HTLV, HBc, HBsAg Negative. Viral Genome Screening Negative. | |||||||||||||||||
| DLS17-036563 | Hepatitis E | France | CPD | 1.00 | 15.00 | $250.00 | 55 Y | M | U/A | <-70C | 07-Oct-15 | Altona HEV RT-PCR Kit | 1,070 copies/mL | WANTAI HEV-IgM Elisa | Negative | WANTAI HEV-IgG Elisa | Negative | $250.00 | Genotype | 3i | Additional Results | HCV, HIV, HTLV, HBc, HBsAg Negative. Viral Genome Screening Negative. | ||||||||||||||||||
| DLS17-036566 | Hepatitis E | France | CPD | 1.00 | 1.00 | $250.00 | 19 Y | M | U/A | <-70C | 22-Mar-16 | Altona HEV RT-PCR Kit | 1,140 copies/mL | WANTAI HEV-IgM Elisa | Positive | WANTAI HEV-IgG Elisa | Negative | $250.00 | Genotype | 3f | Additional Results | HCV, HIV, HTLV, HBc, HBsAg Negative. Viral Genome Screening Negative. | ||||||||||||||||||
| DLS17-036567 | Hepatitis E | France | CPD | 1.00 | 6.00 | $250.00 | 59 Y | M | U/A | <-70C | 03-May-16 | Altona HEV RT-PCR Kit | 15,600 copies/mL | WANTAI HEV-IgM Elisa | Positive | WANTAI HEV-IgG Elisa | Negative | $250.00 | Genotype | 3 | Additional Results | HCV, HIV, HTLV, HBc, HBsAg Negative. Viral Genome Screening Negative. | ||||||||||||||||||
| DLS17-036568 | Hepatitis E | France | CPD | 1.00 | 4.00 | $250.00 | 51 Y | M | U/A | <-70C | 11-Mar-15 | Altona HEV RT-PCR Kit | 8,930 copies/mL | WANTAI HEV-IgM Elisa | Positive | WANTAI HEV-IgG Elisa | 0.39 IU/mL | Positive | $250.00 | Genotype | 3f | Additional Results | HCV, HIV, HTLV, HBc, HBsAg Negative. Viral Genome Screening Negative. | |||||||||||||||||
| DLS17-036570 | Hepatitis E | France | CPD | 1.00 | 4.00 | $250.00 | 52 Y | M | U/A | <-70C | 21-Sep-16 | Altona HEV RT-PCR Kit | <100 copies/mL | WANTAI HEV-IgM Elisa | Positive | WANTAI HEV-IgG Elisa | 3.19 IU/mL | Positive | $250.00 | Genotype | U/A | Additional Results | HCV, HIV, HTLV, HBc, HBsAg Negative. Viral Genome Screening Negative. | |||||||||||||||||
| DLS17-036572 | Hepatitis E | France | CPD | 1.00 | 4.00 | $250.00 | 47 Y | M | U/A | <-70C | 12-Mar-15 | Altona HEV RT-PCR Kit | 4,440 copies/mL | WANTAI HEV-IgM Elisa | Negative | WANTAI HEV-IgG Elisa | Negative | $250.00 | Genotype | 3 | Additional Results | HCV, HIV, HTLV, HBc, HBsAg Negative. Viral Genome Screening Negative. | ||||||||||||||||||
| DLS17-036573 | Hepatitis E | France | CPD | 1.00 | 4.00 | $250.00 | 44 Y | M | U/A | <-70C | 03-Nov-15 | Altona HEV RT-PCR Kit | 243,000 copies/mL | WANTAI HEV-IgM Elisa | Positive | WANTAI HEV-IgG Elisa | 0.90 IU/mL | Positive | $250.00 | Genotype | 3f | Additional Results | HCV, HIV, HTLV, HBc, HBsAg Negative. Viral Genome Screening Negative. | |||||||||||||||||
| DLS17-036574 | Hepatitis E | France | CPD | 1.00 | 7.00 | $250.00 | 41 Y | M | U/A | <-70C | 13-Nov-15 | Altona HEV RT-PCR Kit | <100 copies/mL | WANTAI HEV-IgM Elisa | Negative | WANTAI HEV-IgG Elisa | Negative | $250.00 | Genotype | U/A | Additional Results | HCV, HIV, HTLV, HBc, HBsAg Negative. Viral Genome Screening Negative. | ||||||||||||||||||
| DLS17-036575 | Hepatitis E | France | CPD | 1.00 | 4.00 | $250.00 | 54 Y | M | U/A | <-70C | 01-Dec-16 | Altona HEV RT-PCR Kit | <100 copies/mL | WANTAI HEV-IgM Elisa | Positive | WANTAI HEV-IgG Elisa | 54.33 IU/mL | Positive | $250.00 | Genotype | U/A | Additional Results | HCV, HIV, HTLV, HBc, HBsAg Negative. Viral Genome Screening Negative. | |||||||||||||||||
| DLS17-036577 | Hepatitis E | France | CPD | 1.00 | 13.00 | $250.00 | 38 Y | M | U/A | <-70C | 29-Mar-16 | Altona HEV RT-PCR Kit | 12,300 copies/mL | WANTAI HEV-IgM Elisa | Positive | WANTAI HEV-IgG Elisa | 0.79 IU/mL | Positive | $250.00 | Genotype | 3 | Additional Results | HCV, HIV, HTLV, HBc, HBsAg Negative. Viral Genome Screening Negative. | |||||||||||||||||
| DLS17-036578 | Hepatitis E | France | CPD | 1.00 | 13.00 | $250.00 | 31 Y | M | U/A | <-70C | 25-Apr-16 | Altona HEV RT-PCR Kit | 12,600 copies/mL | WANTAI HEV-IgM Elisa | Positive | WANTAI HEV-IgG Elisa | 0.74 IU/mL | Positive | $250.00 | Genotype | 3f | Additional Results | HCV, HIV, HTLV, HBc, HBsAg Negative. Viral Genome Screening Negative. | |||||||||||||||||
| DLS17-036579 | Hepatitis E | France | CPD | 1.00 | 8.00 | $250.00 | 70 Y | M | U/A | <-70C | 02-Sep-15 | Altona HEV RT-PCR Kit | 7,500 copies/mL | WANTAI HEV-IgM Elisa | Positive | WANTAI HEV-IgG Elisa | 0.33 IU/mL | Positive | $250.00 | Genotype | 3c | Additional Results | HCV, HIV, HTLV, HBc, HBsAg Negative. Viral Genome Screening Negative. | |||||||||||||||||
| DLS17-036580 | Hepatitis E | France | CPD | 1.00 | 4.00 | $250.00 | 27 Y | M | U/A | <-70C | 02-Oct-15 | Altona HEV RT-PCR Kit | 162 copies/mL | WANTAI HEV-IgM Elisa | Positive | WANTAI HEV-IgG Elisa | 0.90 IU/mL | Positive | $250.00 | Genotype | U/A | Additional Results | HCV, HIV, HTLV, HBc, HBsAg Negative. Viral Genome Screening Negative. | |||||||||||||||||
| DLS17-036581 | Hepatitis E | France | CPD | 1.00 | 4.00 | $250.00 | 24 Y | F | U/A | <-70C | 17-Nov-15 | Altona HEV RT-PCR Kit | <100 copies/mL | WANTAI HEV-IgM Elisa | Negative | WANTAI HEV-IgG Elisa | Negative | $250.00 | Genotype | U/A | Additional Results | HCV, HIV, HTLV, HBc, HBsAg Negative. Viral Genome Screening Negative. | ||||||||||||||||||
| DLS17-036582 | Hepatitis E | France | CPD | 1.00 | 4.00 | $250.00 | 54 Y | M | U/A | <-70C | 08-Dec-15 | Altona HEV RT-PCR Kit | <100 copies/mL | WANTAI HEV-IgM Elisa | Negative | WANTAI HEV-IgG Elisa | Negative | $250.00 | Genotype | U/A | Additional Results | HCV, HIV, HTLV, HBc, HBsAg Negative. Viral Genome Screening Negative. | ||||||||||||||||||
| DLS17-036583 | Hepatitis E | France | CPD | 1.00 | 6.00 | $250.00 | 29 Y | M | U/A | <-70C | 29-Jan-16 | Altona HEV RT-PCR Kit | 2,430 copies/mL | WANTAI HEV-IgM Elisa | Positive | WANTAI HEV-IgG Elisa | 0.61 IU/mL | Positive | $250.00 | Genotype | 3f | Additional Results | HCV, HIV, HTLV, HBc, HBsAg Negative. Viral Genome Screening Negative. | |||||||||||||||||
| DLS17-036584 | Hepatitis E | France | CPD | 1.00 | 5.00 | $250.00 | 53 Y | M | U/A | <-70C | 25-Mar-16 | Altona HEV RT-PCR Kit | <100 copies/mL | WANTAI HEV-IgM Elisa | Positive | WANTAI HEV-IgG Elisa | 11.23 IU/mL | Positive | $250.00 | Genotype | U/A | Additional Results | HCV, HIV, HTLV, HBc, HBsAg Negative. Viral Genome Screening Negative. | |||||||||||||||||
| DLS17-036585 | Hepatitis E | France | CPD | 1.00 | 4.00 | $250.00 | 64 Y | F | U/A | <-70C | 02-Feb-16 | Altona HEV RT-PCR Kit | 4,760 copies/mL | WANTAI HEV-IgM Elisa | Positive | WANTAI HEV-IgG Elisa | 5.14 IU/mL | Positive | $250.00 | Genotype | U/A | Additional Results | HCV, HIV, HTLV, HBc, HBsAg Negative. Viral Genome Screening Negative. | |||||||||||||||||
| DLS17-036586 | Hepatitis E | France | CPD | 1.00 | 4.00 | $250.00 | 23 Y | M | U/A | <-70C | 01-Jul-15 | Altona HEV RT-PCR Kit | 224 copies/mL | Sero HEV-IgM | U/A | Sero HEV IgG | U/A | $250.00 | Genotype | 3i | Additional Results | HCV, HIV, HTLV, HBc, HBsAg Negative. Viral Genome Screening Negative. | ||||||||||||||||||
| DLS17-036587 | Hepatitis E | France | CPD | 1.00 | 4.00 | $250.00 | 53 Y | M | U/A | <-70C | 20-Jul-15 | Altona HEV RT-PCR Kit | 554 copies/mL | WANTAI HEV-IgM Elisa | Positive | WANTAI HEV-IgG Elisa | 0.36 IU/mL | Positive | $250.00 | Genotype | 3f | Additional Results | HCV, HIV, HTLV, HBc, HBsAg Negative. Viral Genome Screening Negative. | |||||||||||||||||
| DLS17-036588 | Hepatitis E | France | CPD | 1.00 | 6.00 | $250.00 | 24 Y | M | U/A | <-70C | 18-Aug-15 | Altona HEV RT-PCR Kit | 44,900 copies/mL | WANTAI HEV-IgM Elisa | U/A | WANTAI HEV-IgG Elisa | Negative | $250.00 | Genotype | 3i | Additional Results | HCV, HIV, HTLV, HBc, HBsAg Negative. Viral Genome Screening Negative. | ||||||||||||||||||
| DLS17-036589 | Hepatitis E | France | CPD | 1.00 | 4.00 | $250.00 | 42 Y | M | U/A | <-70C | 18-Dec-15 | Altona HEV RT-PCR Kit | <100 copies/mL | WANTAI HEV-IgM Elisa | Negative | WANTAI HEV-IgG Elisa | Negative | $250.00 | Genotype | U/A | Additional Results | HCV, HIV, HTLV, HBc, HBsAg Negative. Viral Genome Screening Negative. | ||||||||||||||||||
| DLS17-036591 | Hepatitis E | France | CPD | 1.00 | 4.00 | $250.00 | 42 Y | M | U/A | <-70C | 11-May-16 | Altona HEV RT-PCR Kit | 1,360 copies/mL | WANTAI HEV-IgM Elisa | Negative | WANTAI HEV-IgG Elisa | Negative | $250.00 | Genotype | U/A | Additional Results | HCV, HIV, HTLV, HBc, HBsAg Negative. Viral Genome Screening Negative. | ||||||||||||||||||
| DLS17-036593 | Hepatitis E | France | CPD | 1.00 | 4.00 | $250.00 | 30 Y | M | U/A | <-70C | 30-Mar-16 | Altona HEV RT-PCR Kit | 369 copies/mL | WANTAI HEV-IgM Elisa | Positive | WANTAI HEV-IgG Elisa | 1.27 IU/mL | Positive | $250.00 | Genotype | U/A | Additional Results | HCV, HIV, HTLV, HBc, HBsAg Negative. Viral Genome Screening Negative. | |||||||||||||||||
| DLS16-67574 | Hepatitis E | Vietnam | Serum | 1.00 | 8.00 | $250.00 | 55 Y | M | Asian | <-70C | 07-Jun-17 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | 3-Series HepB Vaccine | No | Other Testing Results | | ALT: 1793 U/L | AST: 1680 U/L | ALP: 169 U/L | Bilirubin: 304 umol/L | Serum Creatinine: 79 umol/L | 2-Jun-17 | Current Signs and Symptoms | Fatigue; Jaundice | Co-Infections | None | Current Anti-Viral Therapy | None | Hepatitis Serology | HEV IgM + | 5-Jun-2017 | Acquired Infection Category | U/A | |||||||||
| DLS16-67533 | Hepatitis E | Vietnam | Serum | 1.00 | 10.00 | $250.00 | 47 Y | M | Asian | <-70C | 09-Jun-17 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | 3-Series HepB Vaccine | No | Other Testing Results | | ALT: 186 U/L | AST: 751 U/L | Bilirubin: 82.7 umol/L | Serum Creatinine: 92 umol/L | 8-Jun-17 | Current Signs and Symptoms | Fatigue; Jaundice | Co-Infections | None | Current Anti-Viral Therapy | None | Hepatitis Serology | HEV IgM + | 6-Jun-2017 | Acquired Infection Category | U/A | |||||||||
| DLS16-67489 | Hepatitis E | Vietnam | Serum | 1.00 | 10.00 | $250.00 | 68 Y | F | Asian | <-70C | 06-Jul-17 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | 3-Series HepB Vaccine | No | Other Testing Results | | ALT: 743 U/L | AST: 531 U/L | ALP: 136 U/L | Bilirubin: 258 umol/L | Serum Creatinine: 82 umol/L | 29-Jun-17 | Current Signs and Symptoms | Decreased appetite; Abdominal pain; Fatigue; Jaundice | Co-Infections | None | Current Anti-Viral Therapy | None | Hepatitis Serology | HEV IgM + | 29-Jun-2017 | Acquired Infection Category | U/A | |||||||||
| DLS16-67560 | Hepatitis E | Vietnam | Serum | 1.00 | 10.00 | $250.00 | 44 Y | M | Asian | <-70C | 06-Jul-17 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | 3-Series HepB Vaccine | No | Other Testing Results | | ALT: 82 U/L | AST: 156 U/L | Bilirubin: 18 umol/L | Serum Creatinine: 49 umol/L | 4-Jul-17 | Current Signs and Symptoms | Decreased appetite; Abdominal pain; Fatigue; Jaundice | Co-Infections | None | Current Anti-Viral Therapy | None | Hepatitis Serology | HEV IgM + | 30-Jun-2017 | Acquired Infection Category | U/A | |||||||||
| DLS16-67528 | Hepatitis E | Vietnam | Serum | 1.00 | 14.00 | $250.00 | 29 Y | F | Asian | <-70C | 07-Jul-17 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | 3-Series HepB Vaccine | No | Other Testing Results | | ALT: 210 U/L | AST: 233 U/L | Bilirubin: 87 umol/L | Serum Creatinine: 76 umol/L | 30-Jun-17 | Current Signs and Symptoms | Fatigue; Jaundice | Co-Infections | None | Current Anti-Viral Therapy | None | Hepatitis Serology | HEV IgM + | 6-Jul-2017 | Acquired Infection Category | U/A | |||||||||
| DLS16-67773 | Hepatitis E | Vietnam | Serum | 1.00 | 10.00 | $250.00 | 51 Y | M | Asian | <-70C | 07-Jul-17 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | 3-Series HepB Vaccine | No | Other Testing Results | | ALT: 1851 U/L | AST: 2196 U/L | Bilirubin: 60 umol/L | Serum Creatinine: 82 umol/L | 30-Jun-17 | Current Signs and Symptoms | Abdominal pain; Fatigue; Jaundice | Co-Infections | None | Current Anti-Viral Therapy | None | Hepatitis Serology | HEV IgM + | 6-Jul-2017 | Acquired Infection Category | U/A | |||||||||
| DLS16-67713 | Hepatitis E | Vietnam | Serum | 1.00 | 12.00 | $250.00 | 34 Y | M | Asian | <-70C | 18-Jul-17 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | 3-Series HepB Vaccine | No | Other Testing Results | | ALT: 123 U/L | AST: 352 U/L | Bilirubin: 34 umol/L | Serum Creatinine: 84 umol/L | 14-Jul-17 | Current Signs and Symptoms | Fatigue; Jaundice | Co-Infections | None | Current Anti-Viral Therapy | None | Hepatitis Serology | HEV IgM + | 12-Jul-2017 | Acquired Infection Category | U/A | |||||||||
| DLS16-67795 | Hepatitis E | Vietnam | Serum | 1.00 | 14.00 | $250.00 | 70 Y | M | Asian | <-70C | 14-Jul-17 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | 3-Series HepB Vaccine | No | Other Testing Results | | ALT: 857 U/L | AST: 1133 U/L | Bilirubin: 101.9 umol/L | Serum Creatinine: 82 umol/L | 10-Jul-17 | Current Signs and Symptoms | Decreased appetite; Fatigue; Jaundice | Co-Infections | None | Current Anti-Viral Therapy | None | Hepatitis Serology | HEV IgM + | 13-Jul-2017 | Acquired Infection Category | U/A | |||||||||
| DLS16-67518 | Hepatitis E | Vietnam | Serum | 1.00 | 12.00 | $250.00 | 68 Y | F | Asian | <-70C | 21-Jul-17 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | 3-Series HepB Vaccine | No | Other Testing Results | | ALT: 201 U/L | AST: 478 U/L | Bilirubin: 58.5 umol/L | Serum Creatinine: 78 umol/L | 21-Jul-17 | Current Signs and Symptoms | Fatigue; Jaundice | Co-Infections | None | Current Anti-Viral Therapy | None | Hepatitis Serology | HEV IgM + | 20-Jul-2017 | Acquired Infection Category | U/A | |||||||||
| DLS16-67548 | Hepatitis E | Vietnam | Serum | 1.00 | 9.00 | $250.00 | 63 Y | F | Asian | <-70C | 26-Jul-17 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | 3-Series HepB Vaccine | No | Other Testing Results | | ALT: 203 U/L | AST: 365 U/L | ALP: 186 U/L | LDH: 236 U/L | Bilirubin: 8.3 umol/L | Serum Creatinine: 82 umol/L | 18-Jul-17 | Current Signs and Symptoms | Decreased appetite; Abdominal pain; Fatigue | Co-Infections | None | Current Anti-Viral Therapy | None | Hepatitis Serology | HEV IgM + | 25-Jul-2017 | Acquired Infection Category | U/A | |||||||||
| DLS17-050040-K2 | Hepatitis E | Vietnam | K2 EDTA Plasma | 1.00 | 9.00 | $250.00 | 53 Y | F | Asian | <-70C | 27-Dec-17 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | Hepatitis Serology | HEV IgM + | Acquired Infection Category | U/A | 3-Series HepB Vaccine | No | Other Testing Results | ALT: 90 U/L | AST: 46 U/L | Bilirubin: 38.5 umol/L | Creatinine: 74 umol/L Hepatitis E | 26-Dec-17 | Current Signs and Symptoms | Decreased appetite; Abdominal pain; Fatigue; Jaundice | Co-Infections | None | Current Anti-Viral Therapy | None | ||||||||||
| DLS17-050040-S | Hepatitis E | Vietnam | Serum | 1.00 | 9.00 | $250.00 | 53 Y | F | Asian | <-70C | 27-Dec-17 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | Hepatitis Serology | HEV IgM + | Acquired Infection Category | U/A | 3-Series HepB Vaccine | No | Other Testing Results | ALT: 90 U/L | AST: 46 U/L | Bilirubin: 38.5 umol/L | Creatinine: 74 umol/L Hepatitis E | 26-Dec-17 | Current Signs and Symptoms | Decreased appetite; Abdominal pain; Fatigue; Jaundice | Co-Infections | None | Current Anti-Viral Therapy | None | ||||||||||
| DLS17-050047-K2 | Hepatitis E | Vietnam | K2 EDTA Plasma | 1.00 | 6.00 | $250.00 | 65 Y | F | Asian | <-70C | 21-Dec-17 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | Hepatitis Serology | HEV IgM + | Acquired Infection Category | U/A | 3-Series HepB Vaccine | No | Other Testing Results | ALT: 46 U/L | AST: 78 U/L | Bilirubin: 20.2 umol/L | Creatinine: 59 umol/L Hepatitis E | 15-Dec-17 | Current Signs and Symptoms | Decreased appetite; Abdominal pain; Fatigue; Jaundice | Co-Infections | None | Current Anti-Viral Therapy | None | ||||||||||
| DLS17-050047-S | Hepatitis E | Vietnam | Serum | 1.00 | 5.00 | $250.00 | 65 Y | F | Asian | <-70C | 21-Dec-17 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | Hepatitis Serology | HEV IgM + | Acquired Infection Category | U/A | 3-Series HepB Vaccine | No | Other Testing Results | ALT: 46 U/L | AST: 78 U/L | Bilirubin: 20.2 umol/L | Creatinine: 59 umol/L Hepatitis E | 15-Dec-17 | Current Signs and Symptoms | Decreased appetite; Abdominal pain; Fatigue; Jaundice | Co-Infections | None | Current Anti-Viral Therapy | None | ||||||||||
| DLS17-050057-K2 | Hepatitis E | Vietnam | K2 EDTA Plasma | 1.00 | 8.00 | $250.00 | 38 Y | F | Asian | <-70C | 12-Sep-18 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | Hepatitis Serology | HEV IgM + | Acquired Infection Category | U/A | 3-Series HepB Vaccine | No | Other Testing Results | ALT: 590 U/L | AST: 114 U/L | Bilirubin: 119 umol/L | Creatinine: 64 umol/L Hepatitis E | 6-Sep-18 | Current Signs and Symptoms | Decreased appetite; Abdominal pain; Fatigue; Jaundice | Co-Infections | HBV treatment naive | Current Anti-Viral Therapy | None | ||||||||||
| DLS17-050057-S | Hepatitis E | Vietnam | Serum | 1.00 | 5.00 | $250.00 | 38 Y | F | Asian | <-70C | 12-Sep-18 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | Hepatitis Serology | HEV IgM + | Acquired Infection Category | U/A | 3-Series HepB Vaccine | No | Other Testing Results | ALT: 590 U/L | AST: 114 U/L | Bilirubin: 119 umol/L | Creatinine: 64 umol/L Hepatitis E | 6-Sep-18 | Current Signs and Symptoms | Decreased appetite; Abdominal pain; Fatigue; Jaundice | Co-Infections | HBV treatment naive | Current Anti-Viral Therapy | None | ||||||||||
| DLS17-050066-K2 | Hepatitis E | Vietnam | K2 EDTA Plasma | 1.00 | 9.00 | $250.00 | 69 Y | F | Asian | <-70C | 21-Aug-18 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | Hepatitis Serology | HEV IgM + | Acquired Infection Category | U/A | 3-Series HepB Vaccine | No | Other Testing Results | ALT: 508 U/L | AST: 174 U/L | Bilirubin: 251 umol/L | Creatinine: 51 umol/L Hepatitis E | 17-Aug-18 | Current Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | HBV since 2015, treatment naive | Current Anti-Viral Therapy | None | ||||||||||
| DLS17-050066-S | Hepatitis E | Vietnam | Serum | 1.00 | 7.00 | $250.00 | 69 Y | F | Asian | <-70C | 21-Aug-18 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | Hepatitis Serology | HEV IgM + | Acquired Infection Category | U/A | 3-Series HepB Vaccine | No | Other Testing Results | ALT: 508 U/L | AST: 174 U/L | Bilirubin: 251 umol/L | Creatinine: 51 umol/L Hepatitis E | 17-Aug-18 | Current Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | HBV since 2015, treatment naive | Current Anti-Viral Therapy | None | ||||||||||
| DLS17-050069-K2 | Hepatitis E | Vietnam | K2 EDTA Plasma | 1.00 | 9.00 | $250.00 | 60 Y | M | Asian | <-70C | 28-May-18 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | Hepatitis Serology | HEV IgM + | Acquired Infection Category | U/A | 3-Series HepB Vaccine | No | Other Testing Results | ALT: 482 U/L | AST: 387 U/L | Bilirubin: 558 umol/L | Creatinine: 110 umol/L Hepatitis E | 21-May-18 | Current Signs and Symptoms | Fatigue; Jaundice | Co-Infections | None | Current Anti-Viral Therapy | None | ||||||||||
| DLS17-050069-S | Hepatitis E | Vietnam | Serum | 1.00 | 9.00 | $250.00 | 60 Y | M | Asian | <-70C | 28-May-18 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | Hepatitis Serology | HEV IgM + | Acquired Infection Category | U/A | 3-Series HepB Vaccine | No | Other Testing Results | ALT: 482 U/L | AST: 387 U/L | Bilirubin: 558 umol/L | Creatinine: 110 umol/L Hepatitis E | 21-May-18 | Current Signs and Symptoms | Fatigue; Jaundice | Co-Infections | None | Current Anti-Viral Therapy | None | ||||||||||
| DLS17-050086-K2 | Hepatitis E | Vietnam | K2 EDTA Plasma | 1.00 | 8.00 | $250.00 | 34 Y | M | Asian | <-70C | 25-May-18 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | Hepatitis Serology | HEV IgM + | Acquired Infection Category | U/A | 3-Series HepB Vaccine | No | Other Testing Results | ALT: 212 U/L | AST: 148 U/L | Bilirubin: 137 umol/L | Creatinine: 82 umol/L Hepatitis E | 21-May-18 | Current Signs and Symptoms | Fatigue; Jaundice | Co-Infections | None | Current Anti-Viral Therapy | None | ||||||||||
| DLS17-050086-S | Hepatitis E | Vietnam | Serum | 1.00 | 7.00 | $250.00 | 34 Y | M | Asian | <-70C | 25-May-18 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | Hepatitis Serology | HEV IgM + | Acquired Infection Category | U/A | 3-Series HepB Vaccine | No | Other Testing Results | ALT: 212 U/L | AST: 148 U/L | Bilirubin: 137 umol/L | Creatinine: 82 umol/L Hepatitis E | 21-May-18 | Current Signs and Symptoms | Fatigue; Jaundice | Co-Infections | None | Current Anti-Viral Therapy | None | ||||||||||
| DLS17-050088-K2 | Hepatitis E | Vietnam | K2 EDTA Plasma | 1.00 | 5.00 | $250.00 | 40 Y | M | Asian | <-70C | 07-Sep-18 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | Hepatitis Serology | HEV IgM + | Acquired Infection Category | U/A | 3-Series HepB Vaccine | No | Other Testing Results | ALT: 281 U/L | AST: 233 U/L | Bilirubin: 176 umol/L | Creatinine: 75 umol/L Hepatitis E | 30-Sep-18 | Current Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | None | Current Anti-Viral Therapy | None | ||||||||||
| DLS17-050088-S | Hepatitis E | Vietnam | Serum | 1.00 | 3.00 | $250.00 | 40 Y | M | Asian | <-70C | 07-Sep-18 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | Hepatitis Serology | HEV IgM + | Acquired Infection Category | U/A | 3-Series HepB Vaccine | No | Other Testing Results | ALT: 281 U/L | AST: 233 U/L | Bilirubin: 176 umol/L | Creatinine: 75 umol/L Hepatitis E | 30-Sep-18 | Current Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | None | Current Anti-Viral Therapy | None | ||||||||||
| DLS17-050092-K2 | Hepatitis E | Vietnam | K2 EDTA Plasma | 1.00 | 9.00 | $250.00 | 69 Y | M | Asian | <-70C | 28-May-18 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | Hepatitis Serology | HEV IgM + | Acquired Infection Category | U/A | 3-Series HepB Vaccine | No | Other Testing Results | ALT: 280 U/L | AST: 100 U/L | Bilirubin: 299 umol/L | Creatinine: 77 umol/L Hepatitis E | 16-May-18 | Current Signs and Symptoms | Jaundice | Co-Infections | None | Current Anti-Viral Therapy | None | ||||||||||
| DLS17-050092-S | Hepatitis E | Vietnam | Serum | 1.00 | 9.00 | $250.00 | 69 Y | M | Asian | <-70C | 28-May-18 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | Hepatitis Serology | HEV IgM + | Acquired Infection Category | U/A | 3-Series HepB Vaccine | No | Other Testing Results | ALT: 280 U/L | AST: 100 U/L | Bilirubin: 299 umol/L | Creatinine: 77 umol/L Hepatitis E | 16-May-18 | Current Signs and Symptoms | Jaundice | Co-Infections | None | Current Anti-Viral Therapy | None | ||||||||||
| DLS17-050128-K2 | Hepatitis E | Vietnam | K2 EDTA Plasma | 1.00 | 9.00 | $250.00 | 36 Y | F | Asian | <-70C | 14-Mar-18 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | Hepatitis Serology | HEV IgM + | Acquired Infection Category | U/A | 3-Series HepB Vaccine | Yes | Other Testing Results | ALT: 109 U/L | AST: 218 U/L | Bilirubin: 179 umol/L | Creatinine: 62 umol/L Hepatitis E | 8-Mar-18 | Current Signs and Symptoms | Fatigue; Jaundice | Co-Infections | None | Current Anti-Viral Therapy | None | ||||||||||
| DLS17-050128-S | Hepatitis E | Vietnam | Serum | 1.00 | 7.00 | $250.00 | 36 Y | F | Asian | <-70C | 14-Mar-18 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | Hepatitis Serology | HEV IgM + | Acquired Infection Category | U/A | 3-Series HepB Vaccine | Yes | Other Testing Results | ALT: 109 U/L | AST: 218 U/L | Bilirubin: 179 umol/L | Creatinine: 62 umol/L Hepatitis E | 8-Mar-18 | Current Signs and Symptoms | Fatigue; Jaundice | Co-Infections | None | Current Anti-Viral Therapy | None | ||||||||||
| DLS17-050137-K2 | Hepatitis E | Vietnam | K2 EDTA Plasma | 1.25 | 6.00 | $250.00 | 39 Y | M | Asian | <-70C | 17-Apr-18 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | Hepatitis Serology | HEV IgM + | Acquired Infection Category | U/A | 3-Series HepB Vaccine | No | Other Testing Results | ALT: 108 U/L | AST: 179 U/L | Bilirubin: 273 umol/L | Creatinine: 89 umol/L Hepatitis E | 30-Mar-18 | Current Signs and Symptoms | Abdominal pain; Fatigue; Jaundice | Co-Infections | None | Current Anti-Viral Therapy | None | ||||||||||
| DLS17-050137-S | Hepatitis E | Vietnam | Serum | 1.00 | 7.00 | $250.00 | 39 Y | M | Asian | <-70C | 17-Apr-18 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | Hepatitis Serology | HEV IgM + | Acquired Infection Category | U/A | 3-Series HepB Vaccine | No | Other Testing Results | ALT: 108 U/L | AST: 179 U/L | Bilirubin: 273 umol/L | Creatinine: 89 umol/L Hepatitis E | 30-Mar-18 | Current Signs and Symptoms | Abdominal pain; Fatigue; Jaundice | Co-Infections | None | Current Anti-Viral Therapy | None | ||||||||||
| DLS17-050142-K2 | Hepatitis E | Vietnam | K2 EDTA Plasma | 1.00 | 7.00 | $250.00 | 47 Y | F | Asian | <-70C | 03-Aug-18 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | Hepatitis Serology | HEV IgM + | Acquired Infection Category | U/A | 3-Series HepB Vaccine | No | Other Testing Results | ALT: 894 U/L | AST: 108 U/L | Bilirubin: 17.1 umol/L | Creatinine: 43 umol/L Hepatitis E | 1-Aug-18 | Current Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | None | Current Anti-Viral Therapy | None | ||||||||||
| DLS17-050142-S | Hepatitis E | Vietnam | Serum | 1.00 | 4.00 | $250.00 | 47 Y | F | Asian | <-70C | 03-Aug-18 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | Hepatitis Serology | HEV IgM + | Acquired Infection Category | U/A | 3-Series HepB Vaccine | No | Other Testing Results | ALT: 894 U/L | AST: 108 U/L | Bilirubin: 17.1 umol/L | Creatinine: 43 umol/L Hepatitis E | 1-Aug-18 | Current Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | None | Current Anti-Viral Therapy | None | ||||||||||
| DLS17-050160-K2 | Hepatitis E | Vietnam | K2 EDTA Plasma | 1.00 | 8.00 | $250.00 | 41 Y | M | Asian | <-70C | 06-Aug-18 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | Hepatitis Serology | HEV IgM + | Acquired Infection Category | U/A | 3-Series HepB Vaccine | No | Other Testing Results | ALT: 182 U/L | AST: 541 U/L | Bilirubin: 404 umol/L | Creatinine: 102 umol/L Hepatitis E | 2-Aug-18 | Current Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | None | Current Anti-Viral Therapy | None | ||||||||||
| DLS17-050160-S | Hepatitis E | Vietnam | Serum | 1.00 | 6.00 | $250.00 | 41 Y | M | Asian | <-70C | 06-Aug-18 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | Hepatitis Serology | HEV IgM + | Acquired Infection Category | U/A | 3-Series HepB Vaccine | No | Other Testing Results | ALT: 182 U/L | AST: 541 U/L | Bilirubin: 404 umol/L | Creatinine: 102 umol/L Hepatitis E | 2-Aug-18 | Current Signs and Symptoms | Decreased appetite; Fatigue | Co-Infections | None | Current Anti-Viral Therapy | None | ||||||||||
| DLS17-050179-K2 | Hepatitis E | Vietnam | K2 EDTA Plasma | 1.25 | 7.00 | $250.00 | 52 Y | M | Asian | <-70C | 17-Apr-18 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | Hepatitis Serology | HEV IgM + ; HBsAg + | Acquired Infection Category | U/A | 3-Series HepB Vaccine | No | Other Testing Results | ALT: 289 U/L | AST: 114 U/L | Bilirubin: 475 umol/L | Creatinine: 148 umol/L Hepatitis E and Hepatitis B | 7-Apr-18 | Current Signs and Symptoms | Decreased appetite; Abdominal pain; Fatigue; Jaundice | Co-Infections | HBV treatment naive | Current Anti-Viral Therapy | None | ||||||||||
| DLS17-050179-S | Hepatitis E | Vietnam | Serum | 1.00 | 6.00 | $250.00 | 52 Y | M | Asian | <-70C | 17-Apr-18 | HEV IgM | ELISA | Positive | HEV IgM | $250.00 | Hepatitis Serology | HEV IgM + ; HBsAg + | Acquired Infection Category | U/A | 3-Series HepB Vaccine | No | Other Testing Results | ALT: 289 U/L | AST: 114 U/L | Bilirubin: 475 umol/L | Creatinine: 148 umol/L Hepatitis E and Hepatitis B | 7-Apr-18 | Current Signs and Symptoms | Decreased appetite; Abdominal pain; Fatigue; Jaundice | Co-Infections | HBV treatment naive | Current Anti-Viral Therapy | None |
Keep in mind that all the samples comprised in the Research Sample Biobank represent only a small number of the clinical research specimens available through our Discovery Partners™ clinical research programs. If you can’t find the specific sample type, specimen or biofluids you are looking for please make sure to call our client services group at 805.528.4341 - and ask how we can help support your project from resources available at active clinical sites.
Please read carefully before purchasing:
Clinical specimens for research use only.
Transmissible Infectious Risk! May be HIV, HBV and HCV REACTIVE or of unknown infectious agent test status. Materials provided are derived from human blood, tissue and other bio-fluids. Handle all samples as if capable of transmitting infectious agents. Practice good laboratory technique and dispose of in properly marked medical waste.
If you need help searching for a LARGER SAMPLE SET with specific data elements, please contact our Client Services group who can format Excel spreadsheets for a comprehensive review of all available samples: USA (805) 528-4341
These products are supplied without warranty for suitability for specific applications or analytical determinations.
Specimens and data will be may be used for general biomarker research, assay and instrument validation purposes only. All Research products identified as “Diagnostic Remnant Samples” are human biological materials leftover from routine laboratory analysis and are de-identified (coded) to protect subject confidentiality. Under OHRP definition 45 CFR 46.102(f) these coded specimens are not considered subjects for Human research requiring informed consent. Specimens cannot be used for whole genomic sequencing of genetic material. Research products designated as “Clinical Research Samples” by “type” are obtained from IRB approved research study protocols with informed consent obtained from each subject enrolled. Specimens cannot be used for whole genomic sequencing of genetic material.